Drugmakers scramble to boost leukemia drug supply; Ex-GSK lawyer indicted again;

@FiercePharma: HHS moves to bar Forest CEO from pharma. Story | Follow @FiercePharma

> Hospira, Fresenius and Boehringer Ingelheim are racing to restore U.S. supplies of a scarce leukemia drug while regulators look to imports to meet patient demand. News

> Lauren Stevens, a former lawyer for GlaxoSmithKline, has been reindicted for obstructing a probe into the company's marketing practices after the first indictment was dismissed because of errors by prosecutors. Report

> Indian business officials expect the subcontinent's pharmaceutical industry to reach $20 billion by 2015, making it one of the world's top 10 drug markets. Report

> Cubist Pharmaceuticals posted better-than-expected quarterly earnings driven by strong U.S. and international sales of its flagship antibiotic injection Cubicin, sending its shares up four percent. Story

> Genzyme, a subsidiary of Sanofi-Aventis, has sued two companies for patent infringement related to its Synvisc osteoarthritis product. News

> North Carolina Attorney General Roy Cooper warned that a measure giving immunity to pharmaceutical companies could cost state taxpayers what one legislator described as "hundreds of millions of dollars." Release

> European drug regulators recommended lifting a suspension on Octapharma's immunoglobulin treatment Octagam, allowing the medicine back onto the market in the EU. Item

> For the second time in five years, Public Citizen is petitioning the FDA to ban Roche's Xenical prescription diet pill, which is also marketed by GlaxoSmithKline in a lower-dose, over-the-counter version known as Alli. Report

Biotech News

 @FierceBiotech: Does Eisai's epilepsy drug work? Yes and no. Item | Follow @FierceBiotech

> Lilly, Amylin win EU recommendation for Bydureon. News

> Ex-CEO of InterMune sentenced in fraud case. Story 

> Pfizer's potential blockbuster RA drug reports Phase III success. Item

>  Galapagos ditches its experimental arthritis drug. Report

> After 20 years, Human Genome Sciences nears profitability. Story 

> Biotech VC dollars rise, but deal numbers fall. Item 

And Finally... Astronaut warning: Some drugs intended to treat minor illnesses in space may have shorter shelf lives there than they do on Earth. Report